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Introduction: Influenza vaccine is recommended for
the entire population in Israel. We assessed influenza
vaccine effectiveness (VE) for the 2014/15 and 2015/16
seasons in Israel, for the first time. Methods: Combined
nose and throat swab specimens were collected from
patients with influenza-like illness (ILI) presenting to
sentinel primary care clinics and tested for influenza
virus by RT-PCR. VE of the trivalent inactivated vaccine
(TIV) was assessed using test-negative case–control design. Results: During the 2014/15 season 1,142
samples were collected; 327 (28.6%) were positive
for influenza, 83.8% A(H3N2), 5.8% A(H1N1)pdm09,
9.2% B and 1.2% A un-subtyped. Adjusted VE against
all influenza viruses for this influenza season was
−4.8% (95% confidence interval (CI): −54.8 to 29.0)
and against influenza A(H3N2), it was −15.8% (95%
CI: −72.8 to 22.4). For the 2015/16 season, 1,919 samples were collected; 853 (44.4%) were positive for
influenza, 43.5% A(H1N1)pdm09, 57% B, 0.7% A(H3N2)
and 11 samples positive for both A(H1N1)pdm09 and B.
Adjusted VE against all influenza viruses for this influenza season was 8.8% (95% CI: −25.1 to 33.5), against
influenza A(H1N1)pdm09, it was 32.3% (95% CI: (−4.3
to 56.1) and against influenza B, it was −2.2% (95%
CI: (−47.0 to 29.0). Conclusions: Using samples from
patients with ILI visiting sentinel clinics in Israel, we
demonstrated the feasibility of influenza VE estimation in Israel.

Introduction

Influenza virus infection causes morbidity and mortality worldwide every year [1]. The most effective measure of preventing influenza is the influenza vaccine.
www.eurosurveillance.org

However, influenza vaccine effectiveness (VE) can vary
considerably, both by season [2], and geographic location [2,3].
Israel is a country of 8.5 million people, with a
Mediterranean and arid climate, located in the westernmost part of Asia. In Israel, influenza activity is
seasonal, usually occurring from December through
March [4] in patterns similar to those of Europe and
those in neighbouring Jordan [5] and Egypt [6]. The
outpatient sentinel influenza surveillance system was
established in the 1996/97 season and has been conducted through primary care clinics throughout Israel.
The sentinel clinics are located in all seven districts
of Israel and are staffed by paediatricians, internists
and family physicians. During the 2014/15 and 2015/16
influenza seasons, 23 and 26 sentinel clinics, respectively, participated in influenza surveillance. Israel’s
Ministry of Health recommends influenza vaccination
for the entire population over the age of 6 months [7].
The trivalent inactivated vaccine (TIV), the quadrivalent inactivated vaccine (QIV) and live attenuated influenza vaccine (LAIV) are all registered for use in Israel.
The inactivated vaccines against seasonal influenza
are offered free of charge to all residents through clinics of the four national ‘sick fund’ organisations which
are widely spread throughout the country and are similar to health maintenance organisations in the United
States (US). TIV is the most widely used influenza vaccine in Israel.
In this study we evaluated, for the first time, VE against
medically attended laboratory-confirmed influenza-like
1

Figure 1
Weekly distribution of influenza-positive samples from outpatient sentinel clinics, Israel, influenza seasons 2014/15 and
2015/16
A. 2014/15 influenza season
100

100

Number of samples

60

90
80
70
60
50
40

40

30
20

20

10

Percentage of positive samples (%)

Negative (n = 815)
B (n = 30)
A(unsubtyped) (n = 4)
A(H3) (n = 274)
A(H1N1)pdm09 (n = 19)
% positive

80

0

0
39 40 41

42 43

44 45

46 47

48 49 50 51

52

1

2

3

4

5

6

7

8

9

2014

10

11

12

13

14

15

16

17

18

19

2015

Week and year

B. 2015/16 influenza season

Number of samples

135
120
105
90
75
60

Negative (n = 1,066)
B (n = 476)

100

A(unsubtyped) (n = 0)
A(H3) (n = 6)
A(H1N1)pdm09 (n = 360)
B + A(H1N1)pdm09 (n = 11)
% positive

80

90
70
60
50
40

45

30

30

20

15

10

0

0
40 41

42 43

44 45

46 47

48 49 50 51

52

53

1

2

3

4

5

6

7

2015

8

9

10

11

12

13

14

15

16

17

18

Percentage of positive samples (%)

165
150

19

2016

Week and year

illness (ILI) in the community in Israel using our sentinel surveillance system. The predominant influenza
strain in the 2014/15 season was a drifted influenza
A(H3N2). Influenza A(H1N1)pdm2009 and influenza B
co-circulated in Israel during the 2015/16 season. The
overall influenza vaccination coverage in Israel during the 2014/15 and 2015/16 seasons was ca 21%. The
vaccine coverage was ca 65%, 25% and 40% among
individuals age 65 years of age and over, infants and
children 6 months to 5 years, and individuals less
than 65 years of age with chronic medical conditions,
respectively [8,9].
We used the test-negative case–control design, a commonly used method for estimating influenza VE in
studies that utilise sentinel surveillance systems [10].

2

Methods
Study period and population

Influenza surveillance periods lasted in Israel from
28 September 2014 until 18 April 2015, and from 27
September 2015 until 16 April 2016. During these periods, sentinel clinic providers obtained combined nasal
and throat swabs [11] from a convenience sample of
patients meeting the ILI case definition. The kits of
combined nasal and throat swabs were provided to all
sentinel clinics by the Israel Center for Disease Control.
ILI was defined as a temperature of 37.8˚C and over,
accompanied by one or more of the following symptoms: coryza, sore throat, cough, and muscle ache [12].
Discretion was given to physicians to include other
signs or symptoms considered relevant. Sentinel clinics were asked to send up to ten samples per week.
www.eurosurveillance.org

Figure 2
Flowchart of influenza-like illness patients from sentinel primary care clinics, Israel, influenza seasons 2014/15 and 2015/16
(n = 1,142 and 1,919, respectively)
A. 2014/15 influenza season
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LAIV: live attenuated influenza vaccine; QIV: quadrivalent inactivated influenza vaccine; VE: vaccine effectiveness.

For each patient a questionnaire with demographic,
epidemiologic and clinical data was completed by sentinel medical staff. The data included date of birth,
sex, date of disease onset, date of sample collection
and influenza vaccine status for the evaluated season,
including the date of vaccination and the type of vaccine used. For children less than 9 years of age, providers recorded whether a second dose was needed
(for those receiving the influenza vaccine for the first
time) and the date of the second dose, if indicated.
www.eurosurveillance.org

Information regarding chronic medical conditions placing patients at risk for influenza-related complications
was available for the 2015/16 season.

Molecular identification of influenza viruses in
samples obtained from sentinel patients with
influenza-like illness

The combined nasal and throat samples from sentinel ILI patients were kept at 4˚C in the upright position
until transport. Samples were transported once a week
3

Table 1
Characteristics of samples from influenza-like illness patients eligible for vaccine effectiveness analysis, Israel, influenza
season 2014/15 (n = 1,005)
Influenza types and subtypes of cases (n = 307)
Total A
(n = 277)

A(H1N1)pdm09
(n = 17)

A(H3N2)
(n = 257)

A(unsubtyped)
(n = 3)

B (n = 30)

Total
(n = 1,005)

n (%)a

n (%)a

n (%)a

n (%)a

n (%)a

n (%)a

n (%)b

6 months–17 years

413 (70.2)

165
(28.1)

7 (1.2)

157 (26.7)

1 (0.2)

10 (1.7)

588 (58.5)

18–44 years

193 (68.0)

76
(26.8)

7 (2.5)

68 (23.9)

1 (0.4)

15 (5.3)

284 (28.2)

45–64 years

59 (66.3)

27 (30.3)

2 (2.2)

24 (27.0)

1 (1.1)

3 (3.4)

89 (8.9)

≥ 65 years

33 (75.0)

9 (20.5)

1 (2.3)

8 (18.2)

0 (0)

2 (4.5)

44 (4.4)

Male

360 (69.4)

142
(27.3)

8 (1.5)

133 (25.6)

1 (0.2)

17 (3.3)

519 (51.6)

Female

338 (69.6)

135
(27.8)

9 (1.8)

124 (25.5)

2 (0.4)

13 (2.7)

486 (48.4)

Characteristics

Controls
(n = 698)

p valuec

Age groups

0.83

Sex
0.95

Interval between symptom onset and swab
0–1 days

365 (71.0)

134
(26.1)

7 (1.4)

126 (24.5)

1 (0.2)

15 (2.9)

514 (51.1)

2–4 days

299 (67.0)

133
(29.8)

9 (2.0)

122 (27.3)

2 (0.4)

14 (3.1)

446 (44.4)

5–7 days

34 (75.6)

10 (22.2)

1 (2.2)

9 (20)

0 (0)

1 (2.2)

45 (4.5)

Unvaccinated

577 (69.9)

222
(26.9)

15 (1.8)

204 (24.7)

3 (0.4)

26 (3.1)

825 (82.0)

Vaccinated (TIV)

121 (67.2)

55
(30.6)

2 (1.1)

53 (29.4)

0 (0)

4 (2.2)

180 (17.9)

0.53

Vaccination statusd
0.47

TIV: trivalent inactivated vaccine.
a
Percentage based on total of each row.
b
Percentage based on the total of 1,005.
c
Analysis performed for influenza positive (cases) vs negative (controls).
d
Individuals receiving live attenuated influenza vaccine (LAIV) (n=10) were excluded from the table and analysis.

in cooling containers, by car, to the Central Virology
Laboratory of the Israel Ministry of Health. The samples were tested for influenza by real-time RT-PCR.
The viral genome was extracted from the samples
during the 2014/15 season using NucliSENS easyMAG
(BioMerieux, Marcy l’Etoile, France) and during the
2015/16 season using the KingFisher Purification
System (Thermo Fisher Scientific, Vantaa, Finland) and
the NucleoMag RNA (Macherey-Nagel, Düren, Germany)
RNA extraction kit. Influenza viruses were then tested
by real-time RT-PCR using Applied Biosystems 7500
Real-Time PCR system (Foster City, CA, US) and the
Ambion Ag-Path Master Mix (Life Technologies, US)
and TaqMan Chemistry (Foster City, CA, US) [13-16].
A subset of influenza A(H3N2) circulating in Israel
during the 2014/15 season, and subsets of influenza
A(H1N1)pdm09 and B circulating in Israel during the
2015/16 season underwent nt sequencing of the haemagglutinin (HA) gene. Sequenced viruses were from
samples collected at various stages of each influenza
season. Influenza HA gene-specific primers were used
4

to partially amplify the influenza A and influenza B
HA genes, as previously described according to World
Health Organization (WHO) protocols [17].
Amplified PCR products were sequenced using ABI
PRISM Dye Deoxy Terminator cycle sequencing kit
(Applied Biosystems, Foster City, CA, US). Reaction
mixtures were then analysed using ABI 3500 DNA
Genetic Analyzer (Applied Biosystems, Foster City,
CA, USA). Alignment and comparison of nt sequences
were carried out using the Sequencher software version 5.4 (Gencodes Corporation, Ann Arbor, MI, US). HA
sequences of reference strains used for phylogenetic
analysis were obtained from the EpiFlu database of the
Global Initiative on Sharing All Influenza Data (platform.gisaid.org).

Study design

VE against influenza was assessed for individuals 6
months of age and over who received the TIV, using
the test-negative case–control design [18,19]. VE was
derived as (1−odds ratio (OR)) × 100, expressed as a
www.eurosurveillance.org

Table 2
Characteristics of samples from influenza-like illness patients eligible for vaccine effectiveness analysis, Israel, influenza
season 2015/16 (n = 1,658)
Controls
(n = 873)

Influenza types and subtypes of cases (n = 785)

Total
(n = 1,658)

Total A
(n = 348)a

A(H1N1)pdm09
(n = 332)

A(H3N2)
(n = 5)

A(H1N1)pdm09 + B
(n = 11)

B
(n = 448)a

n (%)b

n (%)b

n (%)b

n (%)b

n (%)b

n (%)b

n (%)c

6 months–17 years

450 (55.2)

129 (15.8)

123 (15.1)

0 (0)

6 (0.7)

242 (29.7)

815 (49.2)

18–44 years

234 (45.0)

142 (27.3)

138 (26.5)

1 (0.2)

3 (0.6)

147 (28.3)

520 (31.4)

45–64 years

131 (58.5)

60 (26.8)

56 (25.0)

3 (1.3)

1 (0.4)

34 (15.2)

224 (13.5)

≥ 65 years

58 (58.6)

17 (17.2)

15 (15.1)

1 (1.0)

1 (1.0)

25 (25.2)

99 (6.0)

Male

434 (52.8)

178 (21.6)

169 (20.6)

3 (0.4)

6 (0.7)

216 (26.3)

822 (49.6)

Female

439 (52.5)

170 (20.3)

163 (19.5)

2 (0.2)

5 (0.6)

232 (27.8)

836 (50.4)

65 (22.9)

284 (17.1)

Characteristics

p
valued

Age groups

0.83

Sex
0.91

Chronic medical conditions
Yes

172 (60.6)

49 (17.2)

45 (15.8)

2 (0.7)

2 (0.7)

No

696 (50.9)

298 (21.8)

286 (20.9)

3 (0.2)

9 (0.7)

5 (71.4)

1 (14.3)

1 (14.3)

0 (0)

0 (0)

Missing

382 (28.0) 1367 (82.4)
1 (14.3)

7 (0.4)

< 0.01

Interval between symptom onset and swab
0–1 days

386 (57.6)

132 (19.7)

124 (18.5)

0 (0)

8 (1.2)

160 (23.9)

670 (40.4)

2–4 days

421 (48.9)

188 (21.9)

182 (21.2)

3 (0.3)

3 (0.3)

254 (29.5)

860 (51.9)

5–7 days

66 (51.6)

28 (21.9)

26 (20.3)

2 (1.6)

0 (0)

34 (26.6)

128 (7.7)

Unvaccinated

742 (52.4)

308 (21.7)

294 (20.8)

3 (0.2)

11 (0.8)

Vaccinated (TIV)

131 (54.1)

40 (16.5)

38 (15.7)

2 (0.8)

0 (0)

< 0.01

Vaccination statuse
377 (26.6) 1416 (85.4)
71 (29.3)

242 (14.6)

0.62

TIV: trivalent inactivated vaccine.
The 11 samples positive for influenza A(H1N1)pdm09 and influenza B are included in both the count of ‹Total A› column and the ‹B› column.
b
Percentage based on total of each row.
c
Percentage based on the total of 1,658.
d
Analysis performed for influenza positive (cases) vs negative (controls).
e
Individuals receiving quadrivalent inactivated influenza vaccine (QIV) (n=12) were excluded from the table and analysis.
a

percentage. VE was estimated for influenza A and B
together and for the specific influenza subtypes, for
each of the two seasons. VE was not calculated for certain influenza types and subtypes if the total number
of positive samples for the type or subtype was very
low, not allowing at least 5 samples in each cell of the
contingency table used for OR calculation. Individuals
were considered vaccinated if they received the influenza vaccine 14 days or more before disease onset.
For children between the ages of 6 months and 9 years
receiving the influenza vaccine for the first time, only
those receiving two doses, with the second dose given
14 days or more before illness, were included in the
analysis. Individuals whose samples were taken more
than 7 days after of onset of symptoms were excluded
from analysis. Because relatively few individuals
received LAIV or QIV during the two influenza seasons,
we estimated VE for TIV only.

Statistical analysis

Percentages were compared using the Mantel-Haenszel
chi-squared test. OR for crude VE calculation was
www.eurosurveillance.org

performed using a univariate logistic regression model
with no covariates. We adjusted for age group, sex,
calendar week of sample collection, days from disease
onset to swab and underlying chronic medical conditions (information regarding chronic conditions was
available for the 2015/16 season only) using multivariable logistic regression. Sensitivity analysis was carried
out to evaluate whether there was a difference between
individuals who were swabbed on days 0–1 from symptom onset and individuals who were swabbed on days
2–7 from symptom onset. Statistical analyses were carried out using SAS version 9.4 (SAS Institute, Cary, NC,
US).

Ethical consideration

Sentinel influenza surveillance in Israel, including the
testing component, is conducted in accordance with
the Public Health Ordinance enacted in Israel and does
not require informed consent. Molecular characterisation of influenza strains isolated from patients was
approved by the ethics committee at the Sheba Medical
Center (1967–15-SMC), Tel Hashomer, Israel.
5

Table 3
Vaccine effectiveness estimates for trivalent inactivated vaccine based on influenza-positive and influenza-negative samples
among cases and controls, Israel, influenza season 2014/15 (n =1,005)
Influenza
type/subtype

A and B

A(H3N2)

Age

Cases

Controls

(n =307)

(n =698)

Crude VE

Vaccinated Unvaccinated

Adjusted VE

Vaccinated

Unvaccinated

All

59

248

121

6 months–17 years

24

151

68

345

19.4 (−33.4 to 51.2)

30.5 (−18.3 to 59.1)b

≥18 years

35

97

53

232

−58.0 (−157.4 to 3.1)

−53.7 (−166.8 to 11.4)b

All

53

204

121

577

−23.9 (−77.6 to 13.6)

−15.8 (−72.8 to 22.4)a

6 months–17 years

24

133

68

345

8.4 (−51.9 to 44.8)

22.7 (−31.7 to 54.6)b

≥ 18 years

29

71

53

232

−78.8 (−202.3 to −5.8)

−75.7 (−216.3 to 2.4)b

577

% (95% CI)

% (95%CI)

−13.4 (−60.2 to 19.7)

−4.8 (−54.8 to 29.0)a

VE: vaccine effectiveness.
a
Adjusted for age group, sex, calendar week and time (days) from symptom onset to swab.
b
Adjusted for sex, calendar week and time (days) from symptom onset to swab.

Results
Influenza season and virus circulation
2014/15 influenza season
During the 2014/15 influenza surveillance season,
1,142 samples were collected from ILI patients. A total
of 327 (28.6%) samples were positive for influenza, of
which 297 (90.8%) samples were positive for influenza
A, and 30 (9.2%) were positive for influenza B. Of the
297 influenza A samples, 274 (92.3%) were A(H3N2), 19
(6.4%) were A(H1N1)pdm09, and 4 (1.3%) were un-subtyped (Figure 1A) [20]. Characterisation of 22 influenza
B samples demonstrated that 21 samples belonged to
the Yamagata lineage and 1 belonged to the Victoria
lineage.
Molecular characterisation of a convenience sample of 22 influenza A(H3N2) viruses from community
sentinel patients, showed that all belonged to the
3C.2a clade, while the vaccine strain influenza A/
Texas/50/2012(H3N2) belonged to the 3C.1 clade. A
detailed description and phylogenetic tree were previously reported [21].
2015/16 influenza season
Of the 1,919 samples that were collected from ILI
patients during the 2015/16 influenza season, a total
of 853 (44.5%) samples were positive for influenza, of
which 377 (44.2%) samples were positive for influenza
A, and 487 (57.1%) were positive for influenza B. Of the
377 influenza A samples, 371 (98.4%) were A(H1N1)
pdm09, and 6 (1.6%) were A(H3N2) (Figure 1B) [4]. A
total of 11 samples (1.3% of the positive influenza samples) were positive for both influenza A(H1N1)pdm09
and influenza B [22].
Molecular characterisation of a convenience sample
of 31 influenza A(H1N1)pdm09 viruses from community sentinel patients, showed that 16 belonged to the
6

6B.1 clade and 15 to the 6B.2 clade, while the vaccine
strain A/California/07/2009(H1N1)pdm09 belonged to
clade 1. Molecular characterisation of 452 Influenza
B viruses demonstrated that 394 (87.2%) belonged to
the Victoria lineage, and 58 (12.8%) belonged to the
Yamagata lineage, while the B components of the trivalent vaccine, B/Phuket/3073/2013, belonged to the
Yamagata lineage [22].

Study population
2014/15 influenza season
Of the 1,142 samples collected from patients with ILI,
127 samples were excluded due to missing vaccination
status or vaccination dates, missing day of symptom
onset, sampling more than 7 days after onset of symptoms, receipt of influenza vaccine less than 14 days
before disease onset, or because of partial vaccination
(children less than 9 years old require two vaccine doses)
(Figure 2). Of the 1,015 remaining ILI patients (316 cases
and 699 controls), 10 received the LAIV (Figure 2); all
10 were less than 13.5 years of age and excluded from
the study. The remaining vaccinated patients received
the trivalent injected egg-grown vaccine (split or inactivated) containing an A/California/7/2009(H1N1)
pdm09-like virus, an A/Texas/50/2012(H3N2)-like virus
and a B/Massachusetts/2/2012-like virus. The characteristics of the 1,005 samples that were included in the
assessment are presented in Table 1.
2015/16 influenza season
Of the 1,919 samples collected from ILI patients, a total
of 249 samples were excluded due to missing vaccination status or vaccination dates, missing day of symptoms onset, sampling more than 7 days after onset of
symptoms, receipt of influenza vaccine less than 14
days before disease onset, partial vaccination (children
less than 9 years old require two vaccine doses) and
missing vaccine type (Figure 2). Of the 1,670 remaining
ILI patients (788 cases and 882 controls), 12 received
www.eurosurveillance.org

Table 4
Vaccine effectiveness estimates for trivalent inactivated vaccine based on influenza-positive and influenza-negative samples
among cases and controls, Israel, influenza season 2015/16 (n = 1,658)

Influenza
type/subtype

A and B

A(H1N1)
pdm09c

Bc

Age

Cases

Controls

(n = 785)

(n = 873)

Crude VE

Adjusted VE

Vaccinated

Unvaccinated

Vaccinated

Unvaccinated

% (95% CI)

% (95%CI)

All

111

674

131

742

6.7 (−22.6 to 29.0)

8.8 (−25.1 to 33.5)a

6 months–17 years

55

310

44

406

≥ 18 years

56

364

87

336

40.6 (14.2 to 58.8)

39.1 (7.8 to 59.8)b

All

38

305

131

742

29.4 (−3.7 to 52.0)

32.3 (−4.3 to 56.1)a

6 months–17 years

17

112

44

406

−40.1 (−154.6 to 22.9)

−8.1 (−104 to 42.7)b

≥ 18 years

21

193

87

336

58.0 (30.1 to 74.7)

56.5 (24.3 to 75.0)b

All

71

377

131

742

−6.7 (−46.1 to 22.1)

−2.2 (−47.0 to 29.0)a

6 months–17 years

38

204

44

406

−71.9 (−173.8 to −7.9)

−25.0 (−106.8 to
24.5)b

≥ 18 years

33

173

87

336

26.3 (−14.5 to 52.6)

26.5 (−20.6 to 55.2)b

−63.7 (−149.9 to −7.2) −25.0 (−98.0 to 21.0)b

Adjusted for age group, sex, calendar week, underlying condition and time (days) from symptom onset to swab.
Adjusted for sex, calendar week, underlying condition and time (days) from symptom onset to swab.
c
The 11 samples positive for influenza A(H1N1)pdm09 and influenza B in the 2015/16 season are included in the analysis of influenza A(H1N1)
pdm09 and influenza B.
a

b

the injectable quadrivalent egg-grown split virus vaccine (QIV) and were excluded from the study. No LAIV
was available in Israel during the 2015/16 influenza
season. The 242 vaccinated individuals received the trivalent injected egg-grown vaccine (split or inactivated)
containing an A/California/7/2009(H1N1)pdm09-like
virus, an A/Switzerland/9715293/2013(H3N2)-like virus
and a B/Phuket/3073/2013-like virus. The characteristics of the 1,658 samples eligible for VE analysis are
detailed in Table 2.

Vaccine effectiveness estimates against
influenza virus
2014/15 influenza season
For the 2014/15 season, adjusted TIV VE against influenza A and B adjusted for age group, gender and calendar week was −4.8% (95% CI: −54.8 to 29.0) (Table 3).
The adjusted VE against the 2014/15 influenza A(H3N2)
was −15.8% (95% CI: −72.8 to 22.4) (Table 3). We did
not calculate VE for influenza A(H1N1)pdm09 or influenza B in the 2014/15 season due to the small number
of positive samples (17 and 30 samples, respectively).
2015/16 influenza season
The adjusted TIV VE against influenza A and B viruses
for 2015/16 season for all ages was 8.8% (95% CI:
−25.1 to 33.5) (Table 4). The adjusted TIV VE against the
2015/16 influenza A(H1N1)pdm09 was 32.3% (95% CI:
−4.3 to 56.1), and the adjusted VE against the 2015/16
influenza B was −2.2% (95% CI: −47.0 to 29.0) (Table
4). Since only five individuals were infected with influenza A(H3N2), no VE analysis was performed for this
subtype.
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Sensitivity analysis

Sensitivity analysis demonstrated substantial differences in VE estimates between individuals who were
swabbed on days 0–1 days vs 2–7 days from disease
onset in the 2014/15 and the 2015/16 seasons (Table
5).

Vaccine effectiveness estimates stratified by age
2014/15 influenza season
For the 2014/15 season, the adjusted TIV VE for influenza A and B were 30.5% (95% CI: −18.3 to 59.1) for
individuals less than 18 years of age, and −53.7% (95%
CI: −166.8 to 11.4) for adults 18 years of age and over.
The adjusted TIV VE against influenza A(H3N2) alone
was 22.7% (95% CI: −31.7 to 54.6) for individuals less
than 18 years of age, and −75.7% (95% CI: −216.3 to
2.4) for adults 18 years and over (Table 3).
2015/16 influenza season
For the 2015/16 season, the adjusted TIV VE for individuals 18 years of age and over was 39.1% (95% CI:
7.8 to 59.8) against any influenza, 56.5% (95% CI: 24.3
to 75.0) against influenza A(H1N1)pdm09, and 26.5%
(95% CI: −20.6 to 55.2) against influenza B (Table 4).
For individuals less than 18 years of age, the adjusted
TIV VE was −25.0% (95% CI: −98.0 to 21.0), against
any influenza, −8.1% (95% CI: −104 to 42.7) against
A(H1N1)pdm09, and −25.0% (95% CI: –106.8 to 24.5)
against influenza B (Table 4).
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Table 5
Sensitivity analysis of trivalent inactivated influenza vaccine effectiveness in preventing medically attended laboratory
confirmed influenza, Israel, influenza seasons 2014/15 and 2015/16 (n = 1,005 and 1,658, respectively)
Influenza
Season

Influenza
Cases
Controls
Time of sample
type/
collection
Vaccinated Unvaccinated Vaccinated Unvaccinated
subtype
A+B

2014/15
A(H3N2)

A+B

2015/16

A(H1N1)
pdm09b

B

b

Crude VE

Adjusted VEa

% (95% CI)

% (95% CI)

< 2 days after
disease onset

34

115

59

306

2–7 days after
disease onset

25

133

62

271

17.8 (−36.6 to 50.6)

20.9 (−39.8 to 55.2)

< 2 days after
disease onset

31

95

59

306

−69.3 (−176.9 to
−3.5)

−61.9 (−183.0 to 7.4)

2–7 days after
disease onset

22

109

62

271

11.8 (−50.6 to 48.3)

14.7 (−153.7 to 52.7)

< 2 days after
disease onset

32

252

52

334

18.4 (−30.5 to 49.0)

22.8 (−29.1 to 53.9)

2–7 days after
disease onset

79

422

79

408

3.3 (−35.9 to 31.2)

1.1 (−49.3 to 34.5)

< 2 days after
disease onset

14

118

52

334

23.8 (−42.6 to 59.3)

−47.8 (−192.4 to 25.3)

2–7 days after
disease onset

24

187

79

408

33.7 (−8.1 to 59.3)

−41.0 (−147.4 to 19.6)

< 2 days after
disease onset

18

142

52

334

18.6 (−44.1 to 54.0)

26.7 (−37.1 to 60.8)

2–7 days after
disease onset

53

235

79

408

−16.5 (−70.9 to 20.6)

−18.5 (−88.8 to 25.6)

−53.3 (−146.2 to 4.5) −41.8 (−144.5 to 17.7)

Adjusted for age group, sex and calendar week for 2014/15, and adjusted for age group, sex, calendar week and underlying condition for
2015/16.
b
The 11 samples positive for influenza A(H1N1)pdm09 and influenza B in the 2015/16 season are included in the analysis of influenza A(H1N1)
pdm09 and influenza B.
a

Discussion

This was the first study in Israel to evaluate influenza
VE in the community using the test-negative case–control design. In this study we evaluated two seasons
with different circulation of influenza viruses. We found
that in the 2014/15 season, which was characterised
by the predominance of a drifted strain of influenza
A(H3N2), the TIV was not effective. These findings are
consistent with reported VE against community influenza A(H3N2) from the UK [18,23], Canada [24], the
US [25-27], Navarra, Spain [28] and Austria [29] in the
same season.
These results are also consistent with the findings of an
Israeli study demonstrating that sera from Israeli individuals vaccinated with the 2014/15 injected split virus
vaccine had reduced ability to neutralise the drifted
influenza A(H3N2) virus [21]. Although the 2014/15
influenza vaccine was not effective against outpatient
influenza A(H3N2) in our study, several studies demonstrated a better VE against preventing influenza
A(H3N2)-associated hospitalisations [30,31], reaching
43% in one study [30].
For the 2015/16 influenza season, which was characterised by the co-dominance of influenza A(H1N1)pdm09
and influenza B, VE estimates varied by virus and age
group. The TIV was moderately effective against influenza A(H1N1)pdm09 in adults over the age of 18 but not
8

in those 6 months to 17 years of age. Low (and not statistically significant) TIV VE was demonstrated against
influenza B in either age group.
Our TIV VE results against influenza A(H1N1)pdm09 in
adults during the 2015/16 season are consistent with
VE results of the inactivated vaccine against laboratory
confirmed influenza A(H1N1)pdm09 in primary care
setting in the US [32], Canada [33], European countries that are part of the Influenza Monitoring Vaccine
Effectiveness in Europe (I-MOVE) [34] and the UK [35].
Likewise, the molecular characterisation results for
influenza A(H1N1)pdm09 in Israel are consistent with
other northern hemisphere results, showing that they
belong to clades 6B.1 and 6B.2 [33,35,36].
Although most influenza B viruses detected in Israel
during the 2015/16 season belonged to the Victoria
lineage, the 2015/16 TIV contained only the Yamagata
lineage. In contrast to the 2015/2016 influenza season,
during the 2012/13 and 2013/14 influenza seasons, the
Yamagata lineage predominated in Israel [37]. Little
influenza B, mostly of the Yamagata lineage, circulated
in Israel during the 2014/15 season. Thus, our low TIV
VE results against influenza B may stem from a lineage mismatch between the dominant influenza B virus
and the 2015/16 TIV influenza B component, along with
reduced exposure to the Victoria lineage in the previous three seasons.
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The low VE against influenza B in 2015/2016 in Israel
differed from VE estimates from the US of 58% (95%
CI: 40 to 70) against the Victoria lineage and 59% (95%
CI: 45 to 69) against the Yamagata Lineage [32,38]. It
also differed from VE estimate of around 50% among
individuals less than 65 years of age in the UK, where,
like in Israel, the Victoria lineage influenza B predominated [35]. Although, the VE of 76.5% (95% CI: 41.9 to
90.5) for those 2 to 17 years of age in the UK can be
attributed, at least in part, to the use of LAIV, the VE
results of individuals between the ages of 18 and 64 in
the UK who mostly received the TIV [35], suggest a different mechanism of protection.
The difference in VE results against influenza A(H1N1)
pdm09 between the two age groups examined in our
study is interesting. The vaccine was moderately effective in adults, a finding consistent with studies from
the UK and US [32,35]. However, the low VE against
influenza A(H1N1)pdm09 in those less than 18 years
of age in Israel differed from VE estimates in the same
age group in those same countries [32,35]. Of particular
note is the difference from the US study, which showed
good VE among children receiving the injectable form
of the influenza vaccine (while low VE estimates were
found among children receiving the LAIV) [32]. It is
worth noting the different vaccination rates among the
adult and child controls in our study in 2015/16. While
the vaccination rate among adult controls was 20.6%,
it was 9.7% among control children (Table 4). By comparison, in the 2014/15 season the vaccination rates
were similar in adult and children controls (18.6% and
16.5%, respectively) (Table 3). The low rate of vaccinated controls in those less than 18 years of age may
have resulted in reduced precision in VE determination.
Our study has several limitations. Our sample size was
initially relatively small. However, we were able to add
additional sentinel clinics for the 2015/16 season and
increase the sample size by ca 40%. In addition, in
both seasons we had a small number of participants
in certain age groups. For this reason, we estimated
VE for age strata of 18 years of age and over and less
than 18 years of age. Further increasing our sample size
in the future will allow stratification into additional age
groups, particularly for seasons in which several influenza types and subtypes co-circulate. For the 2014/15
season we did not collect data regarding chronic medical conditions. However, this information was obtained
during the 2015/16 season.
We used convenience sampling to select patients presenting with ILI, similar to other studies in the field
[3,18], which may have biased our sample. However,
our sentinel clinics represented all seven districts in
the country, and therefore, the sample likely represented larger Israeli society with respect to geography
and population groups.
To evaluate whether our VE estimates might be influenced by the time elapsed from disease onset to swabbing, we conducted a sensitivity analysis. Our analysis
www.eurosurveillance.org

demonstrated substantial differences in VE between
patients with samples obtained 0–1 days after disease
onset compared with patients with samples collected
2–7 days after disease onset. To account for these differences, we adjusted for days from disease onset to
swab in our VE estimation.
We did not have information regarding influenza vaccination in previous years among ILI patients. Thus, we
were unable to measure VE considering previous vaccination status. Influenza vaccination in preceding years
may affect vaccine effectiveness results. Previous
influenza vaccination has been associated with a negative effect on VE in several studies [24,28,39].
In conclusion, using data from a community-based
influenza surveillance system in Israel, we estimated
VE of inactivated influenza vaccine in the Israeli population for the first time. Our study suggests that VE may
vary by season, by influenza type and subtype as well
as by age. Our results, and those of others, support the
need for continued efforts of estimating influenza VE,
both in outpatient and inpatient settings. These efforts
are necessary in order to better understand the factors
that affect influenza VE and to optimise vaccine composition and use. Timely VE estimates are of paramount
importance for the yearly decision regarding influenza
vaccine composition.
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